{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:55:38Z","timestamp":1780059338518,"version":"3.54.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106543","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:38:59Z","timestamp":1775504339000},"source":"Crossref","is-referenced-by-count":1,"title":["When Immunotherapy Hits the Joints: A Case of Late-Onset Polyarthritis Induced by an Immune Checkpoint Blockade and Literature Review"],"prefix":"10.7759","author":[{"given":"Yuenu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Digregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae012","article-title":"Exploring the landscape of immune checkpoint inhibitor-induced adverse events through big data mining of pan-cancer clinical trials","volume":"29","author":"Fadlullah MZ","year":"2024","unstructured":"Fadlullah MZ, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC. Exploring the landscape of immune checkpoint inhibitor-induced adverse events through big data mining of pan-cancer clinical trials. Oncologist. 2024, 29:415-21. 10.1093\/oncolo\/oyae012","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152461","article-title":"Late-onset immune-related adverse events in patients with advanced melanoma: the LATENT study","volume":"17","author":"Pozas J","year":"2025","unstructured":"Pozas J, Cheruvu S, Jaganathan PP, et al.. Late-onset immune-related adverse events in patients with advanced melanoma: the LATENT study. Cancers (Basel). 2025, 17:2461. 10.3390\/cancers17152461","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199031","article-title":"Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study","volume":"14","author":"Liu H","year":"2023","unstructured":"Liu H, Li Y, Li J, et al.. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023, 14:1199031. 10.3389\/fphar.2023.1199031","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331959","article-title":"Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach","volume":"15","author":"Tran SD","year":"2024","unstructured":"Tran SD, Lin J, Galvez C, et al.. Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach. Front Immunol. 2024, 15:1331959. 10.3389\/fimmu.2024.1331959","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine M","year":"2021","unstructured":"Kostine M, Finckh A, Bingham CO, et al.. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021, 80:36-48. 10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter KR","year":"2023","unstructured":"McCarter KR, Wolfgang T, Arabelovic S, et al.. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023, 5:e274-83. 10.1016\/s2665-9913(23)00064-4","journal-title":"Lancet Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach Y","year":"2020","unstructured":"Allenbach Y, Anquetil C, Manouchehri A, et al.. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020, 19:102586. 10.1016\/j.autrev.2020.102586","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00546-2","article-title":"Spectrum and impact of checkpoint inhibitor-induced irAEs","volume":"17","author":"Cappelli LC","year":"2021","unstructured":"Cappelli LC, Bingham CO 3rd. Spectrum and impact of checkpoint inhibitor-induced irAEs. Nat Rev Rheumatol. 2021, 17:69-70. 10.1038\/s41584-020-00546-2","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051237","article-title":"Timeline of adverse events during immune checkpoint inhibitors for advanced melanoma and their impacts on survival","volume":"14","author":"Villa-Crespo L","year":"2022","unstructured":"Villa-Crespo L, Podlipnik S, Anglada N, et al.. Timeline of adverse events during immune checkpoint inhibitors for advanced melanoma and their impacts on survival. Cancers (Basel). 2022, 14:1237. 10.3390\/cancers14051237","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen CN","year":"2021","unstructured":"Owen CN, Bai X, Quah T, et al.. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021, 32:917-25. 10.1016\/j.annonc.2021.03.204","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study","volume":"134","author":"Nigro O","year":"2020","unstructured":"Nigro O, Pinotti G, De Galitiis F, et al.. Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study. Eur J Cancer. 2020, 134:19-28. 10.1016\/j.ejca.2020.04.025","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065643","article-title":"Rheumatic immune-related adverse events due to immune checkpoint inhibitors--a 2023 update","volume":"24","author":"Dang QM","year":"2023","unstructured":"Dang QM, Watanabe R, Shiomi M, et al.. Rheumatic immune-related adverse events due to immune checkpoint inhibitors--a 2023 update. Int J Mol Sci. 2023, 24:5643. 10.3390\/ijms24065643","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts J","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M, et al.. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020, 19:102595. 10.1016\/j.autrev.2020.102595","journal-title":"Autoimmun Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu Y","year":"2020","unstructured":"Liu Y, Jaquith JM, Mccarthy-Fruin K, et al.. Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. 2020, 39:3631-7. 10.1007\/s10067-020-05162-9","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis","volume":"3","author":"Subedi A","year":"2020","unstructured":"Subedi A, Williams SG, Yao L, et al.. Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis. JAMA Netw Open. 2020, 3:e200032. 10.1001\/jamanetworkopen.2020.0032","journal-title":"JAMA Netw Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli LC","year":"2020","unstructured":"Cappelli LC, Grieb SM, Shah AA, Bingham CO 3rd, Orbai AM. Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. BMC Rheumatol. 2020, 4:32. 10.1186\/s41927-020-00133-8","journal-title":"BMC Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya K","year":"2018","unstructured":"Buder-Bakhaya K, Benesova K, Schulz C, et al.. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018, 67:175-82. 10.1007\/s00262-017-2069-9","journal-title":"Cancer Immunol Immunother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh N","year":"2021","unstructured":"Ghosh N, Tiongson MD, Stewart C, Chan KK, Jivanelli B, Cappelli L, Bass AR. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. J Clin Rheumatol. 2021, 27:e317-22. 10.1097\/RHU.0000000000001370","journal-title":"J Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli LC","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017, 69:1751-63. 10.1002\/acr.23177","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15539","article-title":"Immune-related adverse events in urothelial cancer patients: adjustment for immortal time bias","volume":"113","author":"Otsuka H","year":"2022","unstructured":"Otsuka H, Kita Y, Ito K, et al.. Immune-related adverse events in urothelial cancer patients: adjustment for immortal time bias. Cancer Sci. 2022, 113:3912-21. 10.1111\/cas.15539","journal-title":"Cancer Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson JA","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024, 22:582-92. 10.6004\/jnccn.2024.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/aimcc.2022.0815","article-title":"Immune checkpoint inhibitor-induced polyarthritis: a case series","volume":"2","author":"Smith-Uffen M","year":"2023","unstructured":"Smith-Uffen M, Tselios K. Immune checkpoint inhibitor-induced polyarthritis: a case series. Ann Intern Med Clin Cases. 2023, 2:10.7326\/aimcc.2022.0815","journal-title":"Ann Intern Med Clin Cases"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5606\/ArchRheumatol.2019.7041","article-title":"Nivolumab induced seronegative arthritis in a patient with refractory Hodgkin\u2019s lymphoma","volume":"34","author":"\u00c7olak S","year":"2019","unstructured":"\u00c7olak S, Omma A. Nivolumab induced seronegative arthritis in a patient with refractory Hodgkin\u2019s lymphoma. Arch Rheumatol. 2019, 34:112-4. 10.5606\/ArchRheumatol.2019.7041","journal-title":"Arch Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1326734","article-title":"A case of severe seronegative inflammatory arthritis due to nivolumab and review of the literature","volume":"2019","author":"Thapa B","year":"2019","unstructured":"Thapa B, Ali A, Nair R, Vashisht R, Calabrese C. A case of severe seronegative inflammatory arthritis due to nivolumab and review of the literature. Case Rep Rheumatol. 2019, 2019:1326734. 10.1155\/2019\/1326734","journal-title":"Case Rep Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5455\/annalsmedres.2022.12.355","article-title":"Inflammatory polyarthritis induced by nivolumab treatment in a patient with malignant melanoma: a case report","volume":"30","author":"Cure O","year":"2023","unstructured":"Cure O, Ilkkilic K, Altuner M. Inflammatory polyarthritis induced by nivolumab treatment in a patient with malignant melanoma: a case report. Ann Med Res. 2023, 30:530-2. 10.5455\/annalsmedres.2022.12.355","journal-title":"Ann Med Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453030-when-immunotherapy-hits-the-joints-a-case-of-late-onset-polyarthritis-induced-by-an-immune-checkpoint-blockade-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:39:00Z","timestamp":1775504340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453030-when-immunotherapy-hits-the-joints-a-case-of-late-onset-polyarthritis-induced-by-an-immune-checkpoint-blockade-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.106543","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}